Animal and analytical research
AOD-9604
Published research has examined AOD-9604 as a synthetic fragment of human growth hormone in rodent metabolic models and in analytical studies of peptide stability and metabolism.
Research Library
Source-backed research context
Browse concise summaries of published research associated with selected catalogue materials. Evidence type and limitations are stated on every article.
Research articles
For laboratory research use only. Information presented here summarises areas investigated in published research and is not intended as medical advice or as evidence of established effects in humans.
Preclinical evidence
BPC-157
Published preclinical research has examined BPC-157 in gastrointestinal injury models and in experimental tendon, ligament, muscle and tissue-repair settings.
Human phase 2 evidence
Cagrilintide
A multicentre phase 2 trial investigated cagrilintide, a long-acting amylin analogue, using body-mass, safety and tolerability endpoints in adults with overweight or obesity.
Human pharmacology research
CJC-1295 with DAC
Early controlled studies examined the long-acting growth hormone-releasing hormone analogue CJC-1295, including its pharmacokinetic profile and patterns of growth-hormone and IGF-I secretion.
Limited human evidence
DSIP
Small early controlled studies investigated synthetic delta sleep-inducing peptide in human sleep physiology, including short-term and overnight sleep measurements.
Preclinical evidence
GHK-Cu
In vitro and animal research has examined GHK-Cu in extracellular-matrix accumulation, cell proliferation and angiogenesis-related wound models.
Component evidence only
GLOW
No direct peer-reviewed study of the exact GLOW blend was identified. Separate preclinical studies have examined BPC-157 and GHK-Cu in tissue-response and extracellular-matrix models, but those findings do not establish effects for the combined formulation.
Human phase 2 evidence
GLP-3 RT
Published phase 2 research has examined retatrutide as a triple hormone-receptor agonist, including receptor-linked metabolic, body-mass and safety endpoints in adults.
In-vitro evidence
IGF-1 LR3
Cell-culture research has used LR3 IGF-I to examine growth-factor signalling, proliferation and differentiation in primary human skeletal-muscle cells.
Preclinical evidence
Ipamorelin
In vitro and animal studies have examined ipamorelin as a growth-hormone secretagogue, including receptor pharmacology, pituitary-cell responses and skeletal research in rats.
Cell and animal evidence
KPV
Cell and mouse research has examined KPV uptake through the PepT1 transporter and its relationship to inflammatory signalling in intestinal experimental models.
Human clinical evidence
Melanotan I
Melanotan I is identified in published clinical literature as afamelanotide, an alpha-melanocyte-stimulating hormone analogue studied in controlled photobiology trials.
Limited human evidence
Melanotan II
An early pilot phase 1 study investigated Melanotan II as a cyclic melanocortin analogue, recording pigmentation, pharmacodynamic observations and tolerability in a very small volunteer group.
Cell and animal evidence
MOTS-C
Cell and animal studies have examined MOTS-C as a mitochondrially encoded signalling peptide in metabolic homeostasis, cellular stress responses and mitonuclear communication.
Human clinical evidence
PT-141
PT-141 is identified in published literature as bremelanotide, a melanocortin receptor agonist investigated in controlled human pharmacology and phase 3 trials.
Limited human evidence
Selank
Small comparative human studies and animal work have investigated Selank, a synthetic tuftsin analogue, in behavioural, psychometric and neurochemical research contexts.
Limited human evidence
Semax
Small clinical studies have investigated Semax, an ACTH-derived peptide fragment, in neurological research settings using functional, electrophysiological and quality-of-life measures.
Human clinical evidence
SS-31
SS-31 is identified in clinical literature as elamipretide, a mitochondria-targeting peptide studied in controlled trials of primary mitochondrial myopathy and related mitochondrial disorders.
Human clinical evidence
Tesamorelin
Randomised controlled studies have investigated tesamorelin, a growth hormone-releasing hormone analogue, using visceral-adipose, liver-fat, IGF-I and metabolic endpoints in defined adult populations.